Description: Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function.
Home Page: www.savarapharma.com
SVRA Technical Analysis
Building III
Austin,
TX
78746
United States
Phone:
512 614 1848
Officers
| Name | Title |
|---|---|
| Mr. Matthew Pauls | Chairman & CEO |
| Mr. David L. Lowrance CPA | CFO & Sec. |
| Ms. Kate McCabe | Sr. VP of Legal Affairs |
| Ms. Anne Erickson | Sr. VP & Head of Global Bus. Operations |
| Brian Maurer | Head of Clinical Operations |
| Mr. Charles LaPree | Sr. VP of Global Regulatory Affairs & Quality Assurance |
| Dr. Peter Clarke Ph.D. | Exec. VP of Global Technical Operations |
| Dr. Raymond Dennis Pratt FACP, M.D. | Chief Medical Officer |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.4682 |
| Price-to-Sales TTM: | 131146 |
| IPO Date: | 2017-06-01 |
| Fiscal Year End: | December |
| Full Time Employees: | 22 |